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Abstract
Pharmacotherapy of acute post-traumatic tension headaches
consists of analgesics and non-steroidal anti-inflammatory
drugs (NSAIDs). Treatment of chronic tension-type head -
aches consists mainly of tricyclic antidepressants; local injec-
tion of botulinum toxin is one of the comparatively newer
therapeutic options. No data on the treatment of post-trau-
matic headaches with botulinum toxin exist.
A 62-year-old woman with a history of major traumatic brain
injury five years previously developed chronic tension-type
headaches of an oppressive nature. The results of treatment
with oral medication were not satisfactory. The patient was
treated with local injections of 22 IU Botox® into the fronta -
lis muscle and corrugator supercilii muscle. After only five
days, the headaches had improved and after ten days the
patient was free of symptoms even when under stress. 
Sufficiently large-scale clinical studies are now required to
better evaluate the effects of botulinum toxin on post-trau-
matic headaches. 
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CASE REPORT/OPIS PRZYPADKU
St reszc zen ie
W farmakoterapii ostrego pourazowego bólu g³owy typu na -
piêciowego wykorzystuje siê leki przeciwbólowe i niesteroi -
dowe leki przeciwzapalne. Leczenie przewlek³ych bólów
g³owy typu napiêciowego polega g³ównie na podawaniu trój-
pierœcieniowych leków przeciwdepresyjnych. Miejscowe
wstrzykiwanie toksyny botulinowej jest jedn¹ z nowszych
metod leczenia. Nie ma natomiast danych dotycz¹cych zasto-
sowania toksyny botulinowej w pourazowych bólach g³owy.
U 62-letniej kobiety, która piêæ lat wczeœniej dozna³a po wa¿ -
nego urazu mózgu, rozwinê³y siê uci¹¿liwe przewlek³e bóle
g³owy typu napiêciowego. Leki podawane doustnie nie przy-
nios³y zadowalaj¹cej poprawy. Pacjentkê leczono wstrzykniê-
 ciami toksyny botulinowej (22 j. Botoksu®) do miêœnia czo³o -
wego i miêœnia marszcz¹cego brwi. Po up³ywie zaledwie 5 dni
bóle g³owy zmniejszy³y siê, a po 10 dniach pacjentka nie
odczuwa³a bólu g³owy nawet pod wp³ywem stresu.
Dok³adniejsza ocena wp³ywu toksyny botulinowej na poura-
zowe bóle g³owy bêdzie mo¿liwa w badaniach klinicznych na
odpowiednio du¿ych grupach pacjentów.
S³owa kluczowe: toksyna botulinowa, pourazowy ból g³owy,
urazowe uszkodzenie mózgu.
Introduction
Traumatic brain injury (TBI) is common. The annu-
al incidence of this condition is 180-200/100 000 in
Anglo-Saxon countries, with about 300 000/80 mil-
lion/year in Germany [1]. According to the literature,
up to 90% of patients suffer from post-traumatic
headaches [2]. Post-traumatic headaches occur more
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often and persist longer after mild TBI than after major
head injuries. Tension-type headaches are the most com-
mon, accounting for about 85% of all cases [3-5]. Post-
traumatic headaches may be either acute or chronic, the
only difference being that chronic headaches persist for
more than eight weeks after the patient has regained con-
sciousness, or after the injury itself if there was no loss
of consciousness [3]. Post-traumatic headaches are often
associated with autonomic and neurasthenic symptoms
such as dizziness, nausea, fatigue and sleep disturban -
ces, as well as behavioural disorders, mood swings, and
impairment of attention, memory or other cognitive
functions [6]. If the TBI is mild with no loss of con-
sciousness, post-traumatic headaches usually resolve
completely within 6-12 weeks; with major TBI the head -
aches have usually disappeared within a few months, and
only about 20% of those affected still suffer from head -
aches after three years [4,5].
Pharmacotherapy of acute post-traumatic tension
headaches consists of analgesics (acetylsalicylic acid,
paracetamol) and non-steroidal anti-inflammatory drugs
(NSAIDs), e.g. ibuprofen or naproxen [4,5]. How ever,
these should not be prescribed for more than four weeks
because of the risk of causing drug-induced headaches.
On the other hand, treatment of chronic tension head -
aches consists mainly of tricyclic antidepressants such
as amitriptyline, with doxepin and imipramine as alter-
natives or, with strict determination of the indication,
a monoamine oxidase inhibitor (MAO-I), especially if
there is a protracted course with chronification. In addi-
tion to medication, non-pharmacological treatment such
as physiotherapy, massage, heat treatment and learning
muscle relaxation techniques may be useful.
The treatment of headaches with local injections of
botulinum toxin is one of the newer therapeutic options.
Even though there is still no regulatory approval of this
therapy, at least not in Germany, several clinical trials
reporting good results on certain types of headache,
including chronic tension headaches, have already been
published [7-11]. To date, no data on the treatment of
post-traumatic headaches exist. At present, this treat-
ment is only registered for chronic migraine, but has no
approval in other headaches, including tension-type
headache.
Case report
The patient was a 62-year-old woman with a history
of major TBI five years previously. She had been in
a coma for eight days and had had retrograde amnesia
for about 30 days. Initial cranial computed tomography
(CT) showed a large frontal contusion and haematoma
(Fig. 1).
Following the acute medical care, the patient received
early rehabilitation for three months. She reported the
predominantly frontal headaches almost immediately
after regaining consciousness at the neurosurgical inten-
sive care unit. During the first few months, the intensi-
ty of the headaches decreased from 7-8 to 3-4 on the
pain scale, becoming chronic tension-type headaches of
an oppressive nature ‘like an iron band around the head’.
The headaches persisted for five years after the trauma.
Medication in the acute phase started with analgesics
and NSAIDs and progressed to tricyclic antidepressants
after about six weeks. This treatment was supplement-
ed by non-pharmacological therapy (muscle relaxation
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exercises, heat treatment, physiotherapy, and adjuvant
psychotherapy) but the results were not satisfactory. 
The headache occurred continually, with an intensity of 
2-3 on the pain scale. Fatigue and stress exacerbated 
the symptoms to a pain level of 5-6. The initial right-
sided hemiparesis recovered apart from mildly impaired
coordination affecting mainly the arms, while the neu-
ropsychological disorders – primarily an attention deficit
– persisted despite an initial improvement with inten-
sive neuropsychological therapy.
When she came for outpatient follow-up five years
after the TBI, the patient’s main complaint was the post-
traumatic headache, which was adversely affecting her
quality of life and greatly restricting everyday activities,
in particular her social activities. She was therefore
offered treatment with botulinum toxin, which she at
first refused. About four weeks later, she came back ask-
ing to be given a therapeutic trial of botulinum toxin.
Treatment was given with local injections of 22 IU of
onabotulinumtoxin A (Botox®), including four 2 IU
injections into the frontalis muscle, with two 4 IU and
one 6 IU injections into the corrugator supercilii mus-
cle. There were no complications. After only five days,
the headaches had improved to just 1-2 on the pain scale,
and after ten days the patient was free of symptoms even
when under stress. The ‘iron band’ sensation also dis-
appeared completely.
Discussion
Botulinum toxin as a treatment option for headaches
was discovered really by chance, when patients who were
undergoing cosmetic treatment for wrinkles on the fore-
head reported the reduction of headaches as a beneficial
side-effect. Since then, several published studies have
shown that botulinum toxin has a beneficial effect, com-
parable to that of amitriptyline for example, in certain
types of headache [12]; on the other hand, some authors
have not found any definite effects [13,14]. Results from
exploratory trials in episodic migraine or chronic ten-
sion-type headache were equivocal but have suggested
that onabotulinumtoxin A may be useful as preventive
treatment for patients suffering from chronic migraine
[15-20]. Results from the PREEMPT clinical trial
have established onabotulinumtoxin A as a safe, well-
tolerated, and effective headache prophylactic treatment
for chronic migraine [21-23]. Other placebo-controlled,
exploratory studies in patients with episodic migraine
brought negative results [17,24-26]. The efficacy of
botulinum toxin in the treatment of cluster headache and
chronic tension-type headache has not been examined
in large controlled trials.
Botulinum toxin seems to be a good therapeutic
option, especially for chronic headache syndromes and
tension-type headaches [8-11]. In particular, the activ-
ity and tone of the pericranial muscles seem to be good
predictors of treatment success [27]. Experience with
local injections of botulinum toxin for post-traumatic
headaches has not yet been mentioned in the literature.
Given that post-traumatic headaches are common and
the fact that, several years later, 20% of those affected
are still suffering from chronic headaches with some-
times serious restrictions of everyday life, making social
and occupational reintegration difficult, this indication
for botulinum toxin therapy would be a significant addi-
tion to the available therapeutic options. It is all the more
important because the therapy is almost free from
adverse effects, and treatment costs with low doses of
toxin certainly compare favourably with those of other
medications and non-pharmacological therapies.
Conclusions
The patient reported here experienced not only
a reduction in pain but also complete freedom from pain,
even after five years of chronic post-traumatic headaches.
This contributed to considerably greater participation
in everyday and social activities and, in turn, improve-
ment in her quality of life. Sufficiently large-scale clini -
cal studies are now required to better evaluate the effects
of botulinum toxin on post-traumatic headaches. 
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